166 related articles for article (PubMed ID: 20059311)
21. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
[TBL] [Abstract][Full Text] [Related]
23. The recent past and future of adjuvant therapy for pancreatic cancer.
Yeo CJ
Ann Surg Oncol; 2003 Jun; 10(5):488-9. PubMed ID: 12794012
[No Abstract] [Full Text] [Related]
24. Clinical Significance of Adjuvant Surgical Resection for Initially Unresectable Pancreatic Cancer Responsive to Arterial Infusion Chemotherapy.
Doi T; Homma H; Akiyama T; Mezawa S; Takahashi M; Ohi M; Tanaka S; Morii K; Kogawa K; Takeuchi M; Hirata K; Hirano S
Hepatogastroenterology; 2014 May; 61(131):828-33. PubMed ID: 26176081
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
[TBL] [Abstract][Full Text] [Related]
26. Update on combined-modality treatment options for pancreatic cancer.
Willett CG; Clark JW
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 13):29-36. PubMed ID: 14723004
[TBL] [Abstract][Full Text] [Related]
27. The case for routine use of adjuvant therapy in pancreatic cancer.
Kennedy EP; Yeo CJ
J Surg Oncol; 2007 Jun; 95(7):597-603. PubMed ID: 17230543
[TBL] [Abstract][Full Text] [Related]
28. Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
Hamner JB; White M; Crowder C; Singh G
World J Surg Oncol; 2015 Sep; 13():290. PubMed ID: 26419361
[TBL] [Abstract][Full Text] [Related]
29. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
30. [Chemotherapy of pancreatic carcinoma].
Lutz MP
Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
[TBL] [Abstract][Full Text] [Related]
31. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
[TBL] [Abstract][Full Text] [Related]
33. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
Sherman WH; Hecht E; Leung D; Chu K
Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment of pancreatic and ampullary cancer.
Murr MM; Oishi AJ; Toma TP; Sarr MG
J Med Liban; 1995; 43(4):200-7. PubMed ID: 8885553
[No Abstract] [Full Text] [Related]
35. [Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
André T; Balosso J
J Chir (Paris); 1999 Dec; 136(6):309-17. PubMed ID: 10675820
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic adenocarcinoma.
Meslar E
JAAPA; 2020 Nov; 33(11):50-51. PubMed ID: 33109985
[No Abstract] [Full Text] [Related]
37. Management of borderline resectable pancreatic cancer.
Lal A; Christians K; Evans DB
Surg Oncol Clin N Am; 2010 Apr; 19(2):359-70. PubMed ID: 20159519
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic adenocarcinoma.
Eskander MF; Bliss LA; Tseng JF
Curr Probl Surg; 2016 Mar; 53(3):107-54. PubMed ID: 26923296
[No Abstract] [Full Text] [Related]
40. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Golcher H; Brunner TB; Witzigmann H; Marti L; Bechstein WO; Bruns C; Jungnickel H; Schreiber S; Grabenbauer GG; Meyer T; Merkel S; Fietkau R; Hohenberger W
Strahlenther Onkol; 2015 Jan; 191(1):7-16. PubMed ID: 25252602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]